Navigation Links
Moffitt researchers say race affect likelihood of finding suitable stem cell donor
Date:9/10/2012

Researchers at Moffitt Cancer Center and colleagues have published a study describing the greater difficulty in finding matched, unrelated donors for non-Caucasian patients who are candidates for hematopoietic cell transplantation (HCT).

The study appeared in the August issue of Bone Marrow Transplantation.

The success of HCT depends on finding cell donors who are closely matched genetically; as the degree of mismatching increases, the success of unrelated donor HCT falls accordingly. A patient's ideal donor is a genetically matched sibling.

The search for a perfectly matched donor for all groups takes time and affects the progression to transplantation. The National Marrow Donor Program estimates that the genetically matched donor rate is 90 percent for Caucasian patients, 70 percent for Hispanics and Asians, and 60 percent for those of African ancestry.

"Using unrelated adult donors to facilitate HCT has provided major opportunities for patients without a matched sibling donor. In fact, the rate of unrelated donors now exceeds the rate of related donor HCT," said Joseph Pidala, M.D., M.S., assistant member of Moffitt's Blood & Marrow Transplant Department and a member of the Immunology Program. "Using data available at Moffitt, we sought to describe the determinants of a successful, unrelated donor search and to explore the contribution of donor identification versus patient characteristics leading to successful transplantation outcome."

According to Pidala, many patients can achieve prolonged, condition-free survival after unrelated donor HCT. There is, however, a need to understand "modifiable factors" that limit access to unrelated donor HCT.

The researchers concluded that the difficulties in finding well-matched donors in some minority groups were likely related to the degree of genetic heterogeneity within those groups, as well as their underrepresentation in donor pools.

They concluded that when compared to Caucasians, African-Americans, Hispanics and Native Americans have greater difficulty in finding a suitably matched unrelated donor, and less likelihood of successfully reaching HCT. Other barriers to HCT include age and disease progression.

"This research speaks to the need for reducing the time from HCT consultation to donor identification and HCT," Pidala said. "Survival benefit for HCT is dependent upon finding a suitable donor in a timely manner and addressing modifiable barriers to reaching HCT."

"Our data are consistent with the expectation that if suitable unrelated donors could be more expeditiously identified, patient outcomes would improve, particularly for racial and ethnic minorities and for patients with better performance status," concluded Pidala and his colleagues. "Increased representation of ethnic minorities within unrelated donor registries will increase the likelihood of finding a suitable donor."


'/>"/>
Contact: Kim Polacek
kim.polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Moffitt Cancer Center researchers study childhood melanoma characteristics
2. Moffitt Cancer Center researchers find acidic pH microenvironments in tumors aid tumor cell survival
3. Review finds some evidence for chemo brain in breast cancer survivors, Moffitt Cancer Center says
4. Moffitt Cancer Center researchers and colleagues identify PHF20, a regulator of gene P53
5. Moffitt Cancer Center melanoma expert reviews unique adverse events with newly approved drug
6. Moffitt Cancer Center researchers validate molecular signature to predict radiation therapy benefit
7. Moffitt Cancer Center researchers discover how cancer cells hijack a mechanism to grow
8. Attitudes toward outdoor smoking ban at moffitt Cancer Center evaluated
9. Moffitt Cancer Center researcher & colleagues test new drug for patients with neuroendocrine tumors
10. Moffitt Cancer Center researchers find potential key to new treatment for mantle cell lymphoma
11. Moffitt Cancer Center study validates activity of rare genetic variant in glioma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... ... February 17, 2017 , ... Park Cities Pet Sitter President, ... on the Pet Life Radio network. The episode, which was posted this week, ... including: what factors led to Park Cities Pet Sitter’s being awarded the 2017 National ...
(Date:2/18/2017)... (PRWEB) , ... February 18, 2017 , ... ... today provides the latest information and contact points to easily connect elderly veterans ... care, assisted living, and elder-care funding. It also conveys material on this year's ...
(Date:2/17/2017)... ... February 17, 2017 , ... While EHR data has revolutionized ... an innovative workstation designed to reduce nursing fatigue while enhancing productivity. Based on ... offers a lightweight, highly mobile, multi-functional alternative to the limitations of handheld computing. ...
(Date:2/17/2017)... ... February 17, 2017 , ... Wells Pharmacy ... electronic prescribing of controlled and non-controlled substances plus the ability to manage orders ... the United States now accept electronic prescriptions, according to the Office of the ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... **An FDAnews Webinar**, Feb. 22, 2017 — 1:30 p.m. – 2:30 p.m. ... manufacturers should be asking before selecting an FDA approval pathway? , How ...
Breaking Medicine News(10 mins):
(Date:2/19/2017)... February 18, 2017 Marapharm (OTCQB: ... purchase a Medical Delivery Service with the specific and ... between qualified patients and caregivers. The delivery service is ... in the Coachella Valley, California . ... Angeles area to the West, population 19,000,000. ...
(Date:2/17/2017)... Cryoablation, Electrical, Endometrial Hydrothermal, Laser/Light, Microwave, Radiofrequency, Ultrasound, Cardiovascular, Gynaecology, Musculoskeletal, ... to grow at a CAGR of 9.4% from 2017-2022 and CAGR ... a CAGR of 9.5% from 2017 to 2027. The market is ... ... you Read on to discover how you can exploit the ...
(Date:2/17/2017)... plc (NYSE, TASE: PRGO) today announced it has received final ... bitartrate and homatropine methylbromide oral solution (syrup), 5 mg/1.5 mg ... methylbromide oral solution (syrup), 5 mg/1.5 mg per 5 mL ... and children 6 years of age and older. Annual sales ... million.   ...
Breaking Medicine Technology: